Brendy Wauben-Spaetgens

Brendy Wauben-Spaetgens

Auto-generated profile, based on publicly available information

Brendy Wauben-Spaetgens

Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
JHJing de HAAN-DU
Jing de HAAN-DU
KGKlaas H. Groenier
Klaas H. Groenier
BWBrendy Wauben-Spaetgens
Brendy Wauben-Spaetgens
MJMathilde Jalving
Mathilde Jalving
NKNanne Kleefstra
Nanne Kleefstra
GBGeertruida de Bock
Geertruida de Bock
Background: Poor glycemic control prior to cancer diagnosis for patients with preexisting type 2 diabetes (T2DM) may predict a worse cancer diagnosis. We investigated the association between pre-diagnosis glycemic control and all-cause mortality in patients with T2DM who develop cancer. Methods: This prospective cohort study linked data from three sources covering 1989 to 2019: a T2DM benchmarking database, the Netherlands Cancer Registry, and the Personal Records Database. We included patients with T2DM and incident primary breast, colorectal, or prostate cancer (stage 0–III), with target glycemic control defined according to Dutch guidelines. Analysis involved estimating the association between glycemic control and all-cause mortality with Cox proportional hazard models, accounting for individual expected survival relative to the general population and relevant disease (e.g., diabetes duration and medications) and individual (e.g., age and gender) characteristics. Results: Of the 71,648 linked cases, 620 had breast cancer, 774 had colorectal cancer, and 438 had prostate cancer, with follow-up data available for 6.4 (4.2–8.4), 5.6 (2.7–7.6), and 6.3 (4.5–8.2) years, respectively. Compared with patients with pre-diagnosis glycemic control at target, the HRs and 95% confidence intervals for mortality among those with pre-diagnosis glycemic control not at target were 1.40 (1.00–1.96) for breast cancer, 1.45 (1.12–1.88) for colorectal cancer, and 1.39 (0.98–1.98) for prostate cancer. Conclusions: Among patients with T2DM in Dutch primary care, poor glycemic control before diagnosis with breast and colorectal cancer can increase mortality compared with good control. Impact: Glycemic control prior to cancer diagnosis is of prognostic value.


26 November 2025
Verified
Other
Open access
JHJing de HAAN-DU
Jing de HAAN-DU
KGKlaas H. Groenier
Klaas H. Groenier
BWBrendy Wauben-Spaetgens
Brendy Wauben-Spaetgens
MJMathilde Jalving
Mathilde Jalving
NKNanne Kleefstra
Nanne Kleefstra
GBGeertruida de Bock
Geertruida de Bock
The role of glycemic control on mortality among incident cancer patients with T2DM in multivariable analysis, relative to the general population

26 November 2025
Verified
Other
Open access
JHJing de HAAN-DU
Jing de HAAN-DU
KGKlaas H. Groenier
Klaas H. Groenier
BWBrendy Wauben-Spaetgens
Brendy Wauben-Spaetgens
MJMathilde Jalving
Mathilde Jalving
NKNanne Kleefstra
Nanne Kleefstra
GBGeertruida de Bock
Geertruida de Bock
Quality of glycemic control by cancer stage

26 November 2025
Verified
Other
Open access
JHJing de HAAN-DU
Jing de HAAN-DU
KGKlaas H. Groenier
Klaas H. Groenier
BWBrendy Wauben-Spaetgens
Brendy Wauben-Spaetgens
MJMathilde Jalving
Mathilde Jalving
NKNanne Kleefstra
Nanne Kleefstra
GBGeertruida de Bock
Geertruida de Bock
Baseline characteristics of patients diagnosed with type 2 diabetes in Dutch primary care by cancer diagnosis

26 November 2025
Verified
Other
Open access
JHJing de HAAN-DU
Jing de HAAN-DU
KGKlaas H. Groenier
Klaas H. Groenier
BWBrendy Wauben-Spaetgens
Brendy Wauben-Spaetgens
MJMathilde Jalving
Mathilde Jalving
NKNanne Kleefstra
Nanne Kleefstra
GBGeertruida de Bock
Geertruida de Bock
Background:Poor glycemic control prior to cancer diagnosis for patients with preexisting type 2 diabetes (T2DM) may predict a worse cancer diagnosis. We investigated the association between pre-diagnosis glycemic control and all-cause mortality in patients with T2DM who develop cancer.Methods:This prospective cohort study linked data from three sources covering 1989 to 2019: a T2DM benchmarking database, the Netherlands Cancer Registry, and the Personal Records Database. We included patients with T2DM and incident primary breast, colorectal, or prostate cancer (stage 0–III), with target glycemic control defined according to Dutch guidelines. Analysis involved estimating the association between glycemic control and all-cause mortality with Cox proportional hazard models, accounting for individual expected survival relative to the general population and relevant disease (e.g., diabetes duration and medications) and individual (e.g., age and gender) characteristics.Results:Of the 71,648 linked cases, 620 had breast cancer, 774 had colorectal cancer, and 438 had prostate cancer, with follow-up data available for 6.4 (4.2–8.4), 5.6 (2.7–7.6), and 6.3 (4.5–8.2) years, respectively. Compared with patients with pre-diagnosis glycemic control at target, the HRs and 95% confidence intervals for mortality among those with pre-diagnosis glycemic control not at target were 1.40 (1.00–1.96) for breast cancer, 1.45 (1.12–1.88) for colorectal cancer, and 1.39 (0.98–1.98) for prostate cancer.Conclusions:Among patients with T2DM in Dutch primary care, poor glycemic control before diagnosis with breast and colorectal cancer can increase mortality compared with good control.Impact:Glycemic control prior to cancer diagnosis is of prognostic value.